Letters
Covid-19 screening
Mass population screening for SARS-CoV-2 and false positives—why Liverpool shows we have a problem
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4954 (Published 31 December 2020) Cite this as: BMJ 2020;371:m4954- David Cook, chief scientific officer
- Blueberry Therapeutics, Alderley Park, Macclesfield SK10 4TG, UK
- david.cook{at}blueberrytherapeutics.com
In The BMJ’s Editor’s Choice article published on 19 November,1 Abbasi details some of the problems associated with the UK’s proposed mass testing regime. Despite many concerns, not least the ethical issues raised,2 mass testing is now planned for the UK.
As Abbasi says, “Although the false positive rate [of the screen] is small, it is still a problem in a low prevalence setting.” The mass screening trial in Liverpool showed that only …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.